Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care - a podcast by PVI, PeerView Institute for Medical Education
from 2022-02-15T18:00
Go online to PeerView.com/GWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The transformation of patient care in diffuse large b-cell lymphoma (DLBCL), driven by advances with antibodies and cellular therapy, continues—what will this mean for your practice? Find out in PeerView’s “Clinical Consults” video activity where a panel of DLBCL will focus on the applications of these dual innovations in the management of DLBCL. Using a series of alternating case-based discussions and mini-lectures, the panelists use recent science to explore the practice of novel antibodies and CAR-T cell therapy, including: the identification of candidates for treatment with novel antibodies or cellular therapy; the principles of therapeutic sequencing; appropriate safety management and monitoring strategies; and the emergence of novel immunotherapy options in the form of bispecific antibodies. Upon completion of this CE activity, participants will be able to: Summarize the treatment role of novel antibodies and CAR-T options in the management of relapsed diffuse large b-cell lymphoma (DLBCL) as supported by current evidence and clinical practice guidelines, Integrate novel antibody and cellular therapy options, including as sequential therapy, in the management of patients with relapsed/refractory DLBCL, Manage practical considerations associated with antibody and cellular therapy in DLBCL, including confirmation of patient eligibility for treatment, referral to specialized care centers when appropriate, and strategies for mitigating or managing adverse events in patients receiving therapy.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education